Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Website: jnj.com


  • Pretty weak financial results growth rate 8.9% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (11.9%)
  • Dividend yield for the last twelve months 3.0%
  • Free cash flow yield -3.1% (LTM)
  • Share price is 17.7% higher than minimum and 7.2% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (13.6x vs
    )
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: JNJ
Share price, USD:  (+1.5%)167.2
year average price 156.73  


year start price 164.14 2024-08-02

min close price 142.06 2025-01-10

max close price 169.56 2025-07-24

current price 164.74 2025-08-01
Common stocks: 2 631 399 832

Dividend Yield:  3.0%
FCF Yield LTM: -3.1%
EV / LTM EBITDA: 13.6x
EV / EBITDA annualized: 13.8x
Last revenue growth (y/y):  +5.8%
Last growth of EBITDA (y/y):  +12.0%
Historical revenue growth:  +0.6%
Historical growth of EBITDA:  +23.3%
Target EV / EBITDA (hist percentile):
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 439 970
Net Debt ($m): 31 881
EV (Enterprise Value): 471 851
EBITDA LTM ($m): 34 804
EV / LTM EBITDA: 13.6x
Price to Book: 6.2x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-08-01zacks.com

JNJ or AZN: Which Pharma Giant is a Better Buy Post Q2 Results?

2025-07-27247wallst.com

3 Top Dividend Kings I'm Planning on Buying

2025-07-25reuters.com

US FDA says J&J's Ethicon issues correction related to surgical stapler

2025-07-24zacks.com

Why Johnson & Johnson (JNJ) is a Top Momentum Stock for the Long-Term

2025-07-23marketbeat.com

4 Major Stocks Raise 2025 Guidance, Analyst Targets Rise

2025-07-22seekingalpha.com

Johnson & Johnson Stock Could Be Waking Up

2025-07-21zacks.com

Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?

2025-07-21zacks.com

Should J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise?

2025-07-18zacks.com

J&J Expects Oncology Sales of USD 50B by 2030: Can It Achieve the Goal?

2025-07-18proactiveinvestors.com

Spravato sales momentum underscores market potential for psychedelics, atai Life Sciences seen as key beneficiary
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data